FindTrial
Sign In

CS-3150

DRUG11 trials

Sponsors

Daiichi Sankyo, Daiichi Sankyo Co., Ltd.

Conditions

Diabetic NephropathyEssential HypertensionHypertensionHypertension With Moderate Renal ImpairmentMineralocorticoid Receptor AntagonistPrimary AldosteronismSevere Hypertension

Phase 1

The Effect of CS-3150 Exposure on Corrected QT (QTc) Interval Duration in Healthy Volunteers
CompletedNCT04019652
Daiichi SankyoHypertension, Mineralocorticoid Receptor Antagonist
Start: 2015-11-19End: 2015-12-23Updated: 2019-07-15

Phase 2

A Study to Evaluate Efficacy and Safety of CS-3150 in Japanese Hypertensive Subjects
CompletedNCT02345044
Daiichi SankyoEssential Hypertension
Start: 2015-01-31End: 2015-10-31Updated: 2019-10-08
A Study to Evaluate Efficacy and Safety of CS-3150 in Japanese Type 2 Diabetic Subjects With Microalbuminuria
CompletedNCT02345057
Daiichi SankyoDiabetic Nephropathy
Start: 2015-01-31End: 2016-07-31Updated: 2018-12-21
A Phase 2 Exploratory Study of CS-3150 in Japanese Hypertensive Patients With Moderate Renal Impairment
CompletedNCT02448628
Daiichi SankyoHypertension
Start: 2015-05-31End: 2015-12-31Updated: 2019-10-08

Phase 3

Long-term Study of CS-3150 as Monotherapy or in Combination With Other Antihypertensive Drug in Japanese Patients With Essential Hypertension
CompletedNCT02722265
Daiichi Sankyo Co., Ltd.Essential Hypertension
Start: 2016-03-31End: 2017-07-08Updated: 2019-10-08
Study of CS-3150 in Patients With Severe Hypertension
CompletedNCT02808026
Daiichi Sankyo Co., Ltd.Severe Hypertension
Start: 2016-06-30End: 2017-02-28Updated: 2018-12-21
Study of CS-3150 in Hypertensive Patients With Type 2 Diabetes and Albuminuria
CompletedNCT02807974
Daiichi Sankyo Co., Ltd.Hypertension
Start: 2016-06-30End: 2017-03-31Updated: 2018-12-21
Study of CS-3150 in Combination With ARB or ACE Inhibitor in Hypertensive Patients With Moderate Renal Impairment
CompletedNCT02807987
Daiichi Sankyo Co., Ltd.Hypertension With Moderate Renal Impairment
Start: 2016-06-30End: 2017-05-15Updated: 2018-12-21
Study of CS-3150 in Patients With Essential Hypertension
CompletedNCT02890173
Daiichi Sankyo Co., Ltd.Essential Hypertension
Start: 2016-09-30End: 2017-07-11Updated: 2018-12-21

Unknown Phase

Study of CS-3150 Compared to Olmesartan in Patients With Essential Hypertension
CompletedNCT02848170
Daiichi Sankyo Co., Ltd.Essential Hypertension
Start: 2016-08-31End: 2017-04-30Updated: 2018-12-21
Study of CS-3150 in Patients With Primary Aldosteronism
CompletedNCT02885662
Daiichi Sankyo Co., Ltd.Primary Aldosteronism
Start: 2016-09-30End: 2017-07-20Updated: 2018-12-21

Related Papers

Factors Associated with the Antihypertensive Effect of Esaxerenone and Serum Potassium Elevation: A Pooled Analysis of Seven Phase III Studies.
2023-01-206 citations
S-28-2: EFFECT OF ESAXERENONE ON NOCTURNAL BLOOD PRESSURE COMBINED WITH RENIN-ANGIOTENSIN SYSTEM INHIBITOR OR CALCIUM CHANNEL BLOCKER IN UNCONTROLLED HYPERTENSION
Journal of Hypertension2023-01-01
Antihypertensive Effect of Long-Term Monotherapy with Esaxerenone in Patients with Essential Hypertension: Relationship Between Baseline Urinary Sodium Excretion and Its Antihypertensive Effect
Advances in Therapy2022-08-1710 citations
Effect of the Nonsteroidal Mineralocorticoid Receptor Blocker, Esaxerenone, on Nocturnal Hypertension: A <i>Post Hoc</i> Analysis of the ESAX-HTN Study
American Journal of Hypertension2020-10-0232 citations
Double-Blind Randomized Phase 3 Study Comparing Esaxerenone (CS-3150) and Eplerenone in Patients With Essential Hypertension (ESAX-HTN Study)
Hypertension2019-12-02176 citations